On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Phosphoinositide 3-kinase (PI3K) signaling
- Class Ia PI3K's mediate growth factor signaling
- Receptor tyrosine kinase signaling pathway
- Logic network
- Loss-of-function mutations in tumor suppressors
- Sporadic mutations
- Drug targets
- Regulation of metabolism by PI3K AKT signaling
- NVP BEZ235
- Targets of BEZ235 (1)
- Targets of BEZ235 (2)
- Generation of mice with mutant PI3K p110a
- Lung adenocarcinoma requires mutant PI3K
- HIF-1alpha
- Visualizing lung tumors using FDG PET
- mTOR inhibition does not reduce tumor volume
- Will a PI3K inhibitor kill K-Ras driven tumors?
- AKT inhibition does not affect tumor size or activity
- Effects of BEZ235 in K-Ras mutant tumors
- BEZ235 specifically kills PI3K driven tumors
- ARRY 886
- PI3K with MEK inhibitors eradicates K-Ras tumors
- Blocking the PI3K and MAP Kinase pathways
- Inhibition of S6 kinase in K-Ras tumors
- Summary
- References
Topics Covered
- Phosphoinositide 3-kinase (PI3K) signaling
- Class Ia PI3K's and the mediation of growth factor signaling
- The receptor tyrosine kinase signaling pathway
- Loss-of-function mutations in tumor suppressors
- Sporadic mutations
- Drug targets
- Regulation of metabolism by PI3K AKT signaling
- Targets of the drug NVP BEZ235
- Generation of mice with mutant PI3K p110a
- How lung adenocarcinoma requires mutant PI3K
- HIF-1alpha
- Visualizing lung tumors using FDG PET
- How mTOR inhibition does not reduce tumor volume
- Will a PI3K inhibitor kill K-Ras driven tumors?
- How AKT inhibition does not affect tumor size or activity
- Effects of BEZ235 in K-Ras mutant tumors
- How BEZ235 specifically kills PI3K driven tumors
- The drug ARRY 886
- How PI3K with MEK inhibitors eradicates K-Ras tumors
- Blocking the PI3K and MAP Kinase pathways
- Inhibition of S6 kinase in K-Ras tumors
Talk Citation
Cantley, L. (2010, November 30). Role of the PI 3-kinase signaling pathway in cell regulation and human disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/ZQRQ1624.Export Citation (RIS)
Publication History
- Published on November 30, 2010
Financial Disclosures
- Prof. Lew Cantley, Consultant: Novartis.
Hide